Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalised versus non-individualised case-based CME: A randomised pilot study.
Stoevelaar H, Bahl A, Helsen N, Michels NRM, Smets L, Speakman MJ, Stranne J, Toelen J, Van der Aa F, Van Ruysevelt L, Yperman J, Zilli T, Tombal BF, Michel MC. Stoevelaar H, et al. Among authors: smets l. J Eur CME. 2022 Nov 29;11(1):2153438. doi: 10.1080/21614083.2022.2153438. eCollection 2022. J Eur CME. 2022. PMID: 36465494 Free PMC article.
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, Lowe F, O'Leary M, Perez M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Speakman M, et al. Among authors: smets l. Prostate Cancer Prostatic Dis. 2005;8(4):369-74. doi: 10.1038/sj.pcan.4500827. Prostate Cancer Prostatic Dis. 2005. PMID: 16130013
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Lowe FC, et al. Among authors: smets l. Prostate Cancer Prostatic Dis. 2005;8(3):206-9. doi: 10.1038/sj.pcan.4500806. Prostate Cancer Prostatic Dis. 2005. PMID: 15953934
Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
Feio-Azevedo R, Boesch M, Radenkovic S, van Melkebeke L, Smets L, Wallays M, Boeckx B, Philips G, Prata de Oliveira J, Ghorbani M, Laleman W, Meersseman P, Wilmer A, Cassiman D, van Malenstein H, Triantafyllou E, Sánchez C, Aguilar F, Nevens F, Verbeek J, Moreau R, Arroyo V, Denadai Souza A, Clària J, Lambrechts D, Ghesquière B, Korf H, van der Merwe S. Feio-Azevedo R, et al. Among authors: smets l. Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000907. Online ahead of print. Hepatology. 2024. PMID: 38761406
Comparison of the single-cell and single-nucleus hepatic myeloid landscape within decompensated cirrhosis patients.
Van Melkebeke L, Verbeek J, Bihary D, Boesch M, Boeckx B, Feio-Azevedo R, Smets L, Wallays M, Claus E, Bonne L, Maleux G, Govaere O, Korf H, Lambrechts D, van der Merwe S. Van Melkebeke L, et al. Among authors: smets l. Front Immunol. 2024 Feb 6;15:1346520. doi: 10.3389/fimmu.2024.1346520. eCollection 2024. Front Immunol. 2024. PMID: 38380322 Free PMC article.
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
Boesch M, Lindhorst A, Feio-Azevedo R, Brescia P, Silvestri A, Lannoo M, Deleus E, Jaekers J, Topal H, Topal B, Ostyn T, Wallays M, Smets L, Van Melkebeke L, Härtlova A, Roskams T, Bedossa P, Verbeek J, Govaere O, Francque S, Sifrim A, Voet T, Rescigno M, Gericke M, Korf H, van der Merwe S. Boesch M, et al. Among authors: smets l. J Hepatol. 2024 Mar;80(3):397-408. doi: 10.1016/j.jhep.2023.10.039. Epub 2023 Nov 15. J Hepatol. 2024. PMID: 37977244 Free article.
137 results